Pioneering Novel ADC Payloads: Validating Proteasome Inhibitors as a First-in-Class Mechanistic Strategy

• Addressing unmet needs in the current ADC landscape by highlighting the limitations of existing payload classes and the growing necessity for new mechanisms of action
• Introducing the QLi5 proteasome inhibitor platform to demonstrate how non-traditional ADC payloads can be validated and advanced into viable ADC payload strategies
• Discussing how innovative payload mechanisms can broaden the payload landscape for next-generation ADCs

Speakers:

WonGyun Ahn

Associate Director

Qurient